I am a healthcare professional


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.

Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.

By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.

You can find out more about cookies by browsing our Privacy Policy.


For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.

Leave site
Roche and Genentech at

ASH 2021

Coming soon
09:30 AM
Duration 10mins Hall C1
Final Overall Survival Results from BELLINI, a Phase 3 Study of Venetoclax or Placebo in Combination With Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma
Kumar SK, Harrison SJ, Cavo M, de La Rubia J, Popat R, Gasparetto C, Hungria V, Salwender H, Suzuki K, Kim I, Onishi M, Ku G, Pothacamury R, Sehgal V, Masud A, Ross JA, Dobkowska E, Moreau P
12:00 PM
Duration 10mins Hall C1
Cevostamab monotherapy continues to show clinically meaningful activity and manageable safety in patients with heavily pre-treated relapsed/refractory multiple myeloma: updated results from an ongoing Phase I study
Trudel S, Cohen AD, Krishnan A, Fonseca R, Spencer A, Berdeja JG, Lesokhin A, Forsberg PA, Laubach JP, Costa LJ, Rodriguez-Otero P, Kaedbey R, Richter J, Mateos M-V, Thomas SK, Wong C, Li M, Choeurng V, Vaze A, Samineni D, Sumiyoshi T, Cooper J, Harrison S
Duration 10mins Thomas Murphy Ballroom 1-2
Glofitamab as Monotherapy and in Combination with Obinutuzumab Induces High Complete Response Rates in Patients with Multiple Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
Morschhauser F, Carlo-Stella C, Dickinson M, Phillips T, Houot R, Offner F, Haioun C, Corradini P, Hutchings M, Sureda A, Martinez-Lopez J, Wróbel T, Wu S-J, Lundberg L, Mulvihill E, Perez-Callejo D, Relf J, Panchal A, Humphrey K, Bachy E
Duration 10mins Thomas Murphy Ballroom 1-2
Glofitamab Step-Up Dosing Induces High Response Rates in Pts With R/R MCL, Most of Whom Had Failed Prior BTKi Therapy
Phillips T, Dickinson M, Morschhauser F, Bachy E, Crump M, Trnĕný M, Bartlett N, Zaucha J, Humphrey K, Perez-Callejo D, Lundberg L, Relf J, Filezac de L’Etang A, Carlile D, Clark E, Carlo-Stella C
Duration 10mins Thomas Murphy Ballroom 1-2
Mosunetuzumab in Combination With Lenalidomide has a Manageable Safety Profile and Encouraging Activity in Patients With Relapsed/Refractory Follicular Lymphoma: Initial Results From a Phase Ib Study
Morschhauser F, Bishton M, Eyre TA, Bachy E, Cartron G, Ysebaert L, Bobillo S, Gutierrez NC, Budde LE, Fox CP, Knapp A, Yaqub M, Wei MC, O'Hear C, Li H, Purev E, Townsend W
Duration 10mins Thomas Murphy Ballroom 1-2
Mosunetuzumab Monotherapy is an Effective and Well-Tolerated Treatment Option for Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) who have Received ≥2 Prior Lines of Therapy: Pivotal Results from a Phase I/II Study
Budde LE, Sehn LH, Matasar M, Schuster SJ, Assouline S, Giri P, Kuruvilla J, Canales M, Dietrich S, Fay K, Ku M, Nastoupil L, Wei MC, Yin S, Doral MY, Li C-C, Huang H, Negricea R, Penuel E, O'Hear C, Bartlett NL
02:00 PM
Duration 10mins B207-B208
Molecular Responses are Observed Across Mutational Spectrum in Treatment-Naïve Higher-Risk Myelodysplastic Syndrome Patients Treated with Venetoclax plus Azacitidine
Garcia JS, Wei AH, Jacoby MA, Fong CY, Borate U, Baer MR, Cunningham I, Odenike O, Jurcic JG, Nowak D, Peterlin P, Platzbecker U, Dunshee D, Zhou Y, Hoffman D, Sun Y, Popovic R, Ainsworth B, Naqvi K, Kye S, Hogdal L, Garcia-Manero G
Duration 10mins Sidney Marcus Auditorium
Outcomes in Patients with Poor-risk Cytogenetics with or without TP53 Mutations Treated with Venetoclax Combined with Azacitidine
Pollyea DA, Pratz KW, Wei AH, Pullarkat V, Jonas BA, Recher C, Babu S, Schuh AC, Dail M, Sun Y, Potluri J, Chyla B, DiNardo CD
09:30 AM
Duration 10mins C211-C213
Emicizumab Prophylaxis in Persons with Mild or Moderate Hemophilia A: Results from the Interim Analysis of the HAVEN 6 Study
Negrier C, Mahlangu J, Lehle M, Chowdary P, Catalani O, Jimenez-Yuste V, Beckermann BM, Schmitt C, Hermans C, Ventriglia G, Windyga J, Kiialainen A, d'Oiron R, Moorehead P, Teodoro V, Shapiro AD, Oldenburg J
Duration 10mins C211-C213
Emicizumab Outcomes in Hemophilia A Using Real-World Data from the Canadian Hemophilia Bleeding Disorder Registry
Poon M-C, Lee A, Germini F, Keepanasseril A, Ibrahim Q, Nissen F, Sanabria F, Santos M, Iserman E, Matino D, Iorio A
04:30 PM
Duration 10mins Thomas Murphy Ballroom 1-2
Glofitamab in Combination with Polatuzumab Vedotin: Phase Ib/II Preliminary Data Support Manageable Safety and Encouraging Efficacy in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
Hutchings M, Sureda A, Terol MJ, Bosch F, Corradini P, Stauffer Larsen T, Rueda Dominguez A, Panchal A, Bottos A, Wang Y, Filézac de L’Etang A, Tandon M, Sellam G, Gritti G
Duration 10mins Thomas Murphy Ballroom 3-5
Mosunetuzumab Plus Polatuzumab Vedotin has Promising Efficacy and a Favorable Safety Profile in Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma: Updated Results from a Phase Ib/II Study
Budde LE, Olszewski A, Assouline S, Kamdar M, Diefenbach C, Ghosh N, Lossos IS, Mehta A, Sabry W, Dorritie K, Pham S, Xu J, Huw L-Y, To I, Oki Y, O'Hear C, Chavez J
Duration 10mins B211-B212
Venetoclax and Azacitidine in the Treatment of Patients with Relapsed/Refractory Myelodysplastic Syndrome
Zeidan AM, Borate U, Pollyea DA, Brunner AM, Roncolato F, Garcia JS, Filshie RJ, Odenike O, Watson A-M, Bajel A, Naqvi K, Zha J, Hogdal L, Zhou Y, Hoffman D, Kye S, Garcia-Manero G
10:30 AM
Duration 10mins B312-B314
A Novel Methodology for Building Longitudinal, Patient-Centric Real World Datasets in Hemophilia A
Skinner MW, Hanson G, Xu T, Ofori-Asenso R, Ko RH, Cibelli E, Nissen F, Witkop M, Sanabria F, Shapiro AD
02:45 PM
Duration 10mins B308-B309
Venetoclax in Combination with Gilteritinib Demonstrates Molecular Clearance of FLT3 Mutation in Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia
Daver N, Perl AE, Maly J, Levis M, Ritchie E, Litzow M, McCloskey J, Smith CC, Schiller G, Bradley T, Tiu RV, Naqvi K, Dail M, Siddani S, Wang J, Chyla B, Lee P, Altman JK
09:00 AM
Duration 10mins Hall C2-C3
The POLARIX Study: Polatuzumab Vedotin with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma
Tilly H, Morschhauser F, Sehn LH, Friedberg JW, Trněný M, Sharman JP, Herbaux C, Burke JM, Matasar M, Rai S, Izutsu K, Mehta-Shah N, Oberic L, Chauchet A, Jurczak W, Song Y, Greil R, Mykhalska L, Bergua Burgués JM, Cheung MC, Pinto A, Shin HJ, Hapgood G, Munhoz E, Abrisqueta P, Gau JP, Hirata J, Jiang Y, Yan M, Lee C, Flowers C, Salles G